Ładuje się......
Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs
HER2-positive breast cancer is an aggressive tumour that affects approximately one in five breast cancer women. Clinical studies have shown that HER2-positive cancer have different characteristics from other mammary tumors: a more rapid progression of the disease, an earlier age of onset (women of c...
Zapisane w:
Główni autorzy: | , |
---|---|
Format: | Artigo |
Język: | Inglês |
Wydane: |
AboutScience Srl
2018-10-01
|
Seria: | AboutOpen |
Hasła przedmiotowe: | |
Dostęp online: | https://journals.aboutscience.eu/index.php/aboutopen/article/view/135 |
Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|